Skip to main content
. 2021 Dec 20;45(1):45–64. doi: 10.1007/s40264-021-01127-2

Fig. 5.

Fig. 5

Any-grade treatment-emergent adverse events leading to ramucirumab or placebo dose adjustment in three or more patients in the RAM + ERL arm in RELAY. ERL erlotinib, PBO placebo, RAM ramucirumab